{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:24:32Z","timestamp":1786119872126,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/mol.0b013e32834701c3","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T03:52:27Z","timestamp":1303789947000},"page":"270-276","source":"Crossref","is-referenced-by-count":11,"title":["Hyperlipidaemia and cardiovascular disease"],"prefix":"10.1097","volume":"22","author":[{"given":"Sandeep A.","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit R.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20211004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2009.11.010","article-title":"The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.","volume":"210","author":"Shah","year":"2010","journal-title":"Atherosclerosis"},{"key":"R2-5-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPAR): at the crossroads of obesity, diabetes and cardiovascular disease.","volume":"205","author":"Fruchart","year":"2009","journal-title":"Atherosclerosis"},{"key":"R3-5-20211004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1358\/dot.2006.42.1.893618","article-title":"Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.","volume":"42","author":"Fruchart","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"R4-5-20211004","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/HCO.0b013e32832c0b3d","article-title":"Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidemia.","volume":"24","author":"Wierzbicki","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"R5-5-20211004","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11892-010-0124-4","article-title":"Management of hypertriglyceridemia in the diabetic patient.","volume":"10","author":"Jialal","year":"2010","journal-title":"Curr Diab Rep"},{"key":"R6-5-20211004","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R7-5-20211004","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2337\/diacare.15.7.820","article-title":"Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.","volume":"15","author":"Koskinen","year":"1992","journal-title":"Diabetes Care"},{"key":"R8-5-20211004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R9-5-20211004","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density lipoprotein Intervention Trial (VA-HIT).","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch Int Med"},{"key":"R10-5-20211004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL-C cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"R11-5-20211004","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects on long-term fenofibrate therapy on cardiovascular events in 9795 in the people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial.","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"R12-5-20211004","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"for the ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-5-20211004","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"for the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"R14-5-20211004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2337\/diab.18.5.285","article-title":"A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy.","volume":"18","author":"Harrold","year":"1969","journal-title":"Diabetes"},{"key":"R15-5-20211004","first-page":"594","article-title":"Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent Article in German.","volume":"89","author":"Freyberger","year":"1994","journal-title":"Med Klin (Munich)"},{"key":"R16-5-20211004","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"R17-5-20211004","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"for the ACCORD Study Group and the ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes.","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-5-20211004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R19-5-20211004","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"R20-5-20211004","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-151-9-200911030-00144","article-title":"Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.","volume":"151","author":"Sharma","year":"2009","journal-title":"Ann Intern Med"},{"key":"R21-5-20211004","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"R22-5-20211004","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.clinthera.2004.10.008","article-title":"Comparison of fluvastatin-fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin Ther"},{"key":"R23-5-20211004","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1185\/03007995.2010.503429","article-title":"The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis.","volume":"26","author":"Wierzbicki","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R25-5-20211004","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ahj.2007.07.011","article-title":"The role of fibrates in the prevention of cardiovascular disease: a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.","volume":"154","author":"Saha","year":"2007","journal-title":"Am Heart J"},{"key":"R26-5-20211004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: a pooled meta-analysis of randomized placebo-controlled clinical trials.","volume":"141","author":"Saha","year":"2010","journal-title":"Int J Cardiol"},{"key":"R27-5-20211004","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and metaanalysis.","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"R28-5-20211004","first-page":"379","article-title":"W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up.","volume":"2","year":"1980","journal-title":"Lancet"},{"key":"R29-5-20211004","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MOL.0b013e32833c1e74","article-title":"Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.","volume":"21","author":"Wierzbicki","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"R30-5-20211004","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.amjcard.2010.07.041","article-title":"Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.","volume":"106","author":"Enger","year":"2010","journal-title":"Am J Cardiol"},{"key":"R31-5-20211004","first-page":"74","article-title":"Fibrates plus betaine: a winning combination N Z Med","volume":"123","author":"Lever","year":"2010","journal-title":"J"},{"key":"R32-5-20211004","first-page":"525","article-title":"Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.","volume":"6","author":"Moutzouri","year":"2010","journal-title":"Vasc Health Risk Manag"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00041433-201108000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:23:43Z","timestamp":1786044223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00041433-201108000-00005"}},"subtitle":["do fibrates have a role?"],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e32834701c3","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}